12:56 PM
Nov 29, 2018
 |  BC Innovations  |  Translation in Brief

Predicting respiratory response

How an IL-17A-related gene signature could identify COPD patient subgroups

A University of California San Francisco team has described a gene signature that identifies a subgroup of chronic obstructive pulmonary disease (COPD) patients who could benefit from IL-17A inhibitors if they don’t respond to corticosteroids.

Standard of care for COPD comprises inhaled long-acting muscarinic antagonists (LAMAs) and long-acting β agonists (LABAs) for symptomatic relief, plus anti-inflammatory inhaled corticosteroids in patients with COPD exacerbations or concomitant asthma. But according to author Stephanie Christenson, about half of the patients do not respond to standard of care, and many without...

Read the full 418 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >